Post Chemotherapy RPLND in Patients with Elevated Markers: Current Concepts and Clinical Outcome

Urologic Clinics of North America

Volumn 34, Issue 2, 2007, Pages 219-225

  Beck, Stephen D W ^a   Foster, Richard S ^a   Bihrle, Richard ^a   Einhorn, Lawrence H ^a   Donohue, John P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CHORIONIC GONADOTROPIN; PLATINUM DERIVATIVE;

ADJUVANT CHEMOTHERAPY; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DISEASE MARKER; FIBROSIS; GERM CELL TUMOR; HUMAN; LYMPH NODE DISSECTION; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TERATOMA; UNITED STATES; UNIVARIATE ANALYSIS;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; RETROPERITONEAL SPACE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34247615057     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2007.02.006     Document Type: Review

References (15)

1. Steyerberg E.W., Keizer H.J., Fossa S.D., et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 13 5 (1995) 1177-1187
2. Fox E.P., Weathers T.D., Williams S.D., et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11 7 (1993) 1294-1299
3. Beck S.D., Foster R.S., Bihrle R., et al. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 23 25 (2005) 6149-6156
4. Albers P., Ganz A., Hannig E., et al. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 164 2 (2000) 381-384
5. Wood Jr. D.P., Herr H.W., Motzer R.J., et al. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer 70 9 (1992) 2354-2357
6. van der Gaast A., Hoekstra J.W., Croles J.J., et al. Elevated serum tumor markers in patients with testicular cancer after induction chemotherapy due to a reservoir of markers in cystic differentiated mature teratoma. J Urol 145 4 (1991) 829-831
7. Beck S.D., Patel M.I., and Sheinfeld J. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors. J Urol 171 1 (2004) 168-171
8. Eastham J.A., Wilson T.G., Russell C., et al. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology 43 1 (1994) 74-80
9. Coogan C.L., Foster R.S., Rowland R.G., et al. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology 50 6 (1997) 957-962
10. Murphy B.R., Breeden E.S., Donohue J.P., et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 11 2 (1993) 324-329
11. Ravi R., Ong J., Oliver R.T., et al. Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. Br J Urol 81 6 (1998) 884-888
12. Donohue J.P., Leviovitch I., Foster R.S., et al. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol 16 2 (1998) 65-71
13. McKiernan J.M., Motzer R.J., Bajorin D.F., et al. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology 62 4 (2003) 732-736
14. Davis B.E., Herr H.W., Fair W.R., et al. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol 152 1 (1994) 111-113 [discussion: 114]
15. Saxman S.B., Nichols C.R., Foster R.S., et al. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. J Urol 155 2 (1996) 587-589